dichloromethane (DCM) (3 x 50 mL) and the solvent removed via rotary evaporation. The resulting solid was dissolved in methanol, filtered, and the solvent removed via rotary evaporation. The furnished solid was purified via reverse-phase flash chromatography using an acetonitrile to water gradient (3% to 95%) over 30 min to furnish the desired material as a dark blue solid in 37.2% yield.
1 H NMR (400 MHz, DMSO-d6) δ 9.62 (broad, 5H), 8.212 (t, J = 9.2 Hz, 1H), 8.208 (t, J = 8.8 Hz, 1H), 8.044 (s, 1H), 7.787 (t, J = 3.2 Hz, 1H), 7.787 (t, J = 4.4Hz, 1H), 7.236 (d, J = 8.4 Hz, 2H), 7.240 (d, J = 8.4 Hz, 2H), 3.611 (s, 2H), 2.537 (s, 1H); 13 C NMR (100 MHz, CDCl3) δ 182. 506, 181.971, 172.859, 144.138, 142.695, 141.011, 137.861, 134.155, 133.613, 133.202, 132.858, 131.349, 130.815, 126.090, 126.017, 123.034, 122.735, 111.513, 109.543; 
Synthesis of Fluorophore/Dye-Labeled Peptides
Peptides were synthesized using standard Fmoc solid-phase synthesis on a Prelude peptide synthesizer (Protein Technologies Inc., Tucson, AZ, U.S.A.). Novasyn TGR resin was swelled for 30 min in DCM before synthesis. Fmoc-Lys(Mtt)-OH was then coupled using 5.0 equiv AA, 4.9 equiv of HCTU, 20 equiv of diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF) (2 × 5 min) followed by a DMF wash (6 × 30 s). The Lys 4-methyltrityl protecting group was then deprotected using 7% TFA/7% TIS/86% DCM. The deprotected side chain amine was then acylated using 1.1 equiv cAB40, 1.0 equiv HCTU, and 20.0 equiv DIPEA in DMF (2 x 2 h). The Fmoc-protecting group was removed using 20% piperidine in DMF (2 × 2.5 min) followed by a DMF wash (6 × 30 s). Fmoc-Arg-OH and Fmoc-Gly-OH were then to the free N-terminus of the peptide using the conditions described for the coupling and deprotection of Fmoc-Lys(Mtt)-OH. In the case of 11, the photolabile amino acid S3 was coupled instead of Fmoc-Arg-OH. The Nterminal Fmoc was then removed using 20% piperidine in DMF (2 × 2.5 min) and fluorophores were coupled using one of two methods. (1) The fluorophores DECou, Cou343, 5'-FAM, TAM, and ROX were coupled to the N-terminal amine using 5.0 equiv of fluorophore, 4.9 equiv of HCTU, and 20 equiv of DIPEA in DMF (1× 60 min) followed by a wash (3× DMF, IPA, DCM). (2) The fluorophores atto610-NHS ester and atto700-NHS ester were coupled using 1.0 mg of dye and 20 equiv of DIPEA in DMF (1 × 60 min) followed by a wash (3X DMF, IPA, DCM). The synthesis of peptides 13, 15, and 16 followed the exact same procedure as above, but the Mtt protecting group deprotection and cAB40 coupling was skipped. The synthesis of peptide 14 followed the exact same procedure as above, but fluorophore coupling was skipped to leave a free N-terminal amine. After synthesis was complete, the peptide was cleaved from the resin and deprotected using a 95:2.5:2.5 TFA:H2O:triisopropylsilane (TIPS) cleavage cocktail. The peptides were isolated via filtration, precipitated with ice-cold ether, and centrifuged. The precipitates were air-dried, dissolved in DMSO, and purified using HPLC (3% to 95% acetonitrile to water gradient with 0.1% TFA over 30 min using a 25 cm x 21.2 mm C18 column). Peptides 5 -11 were collected, freeze-dried, and characterized by matrixassisted laser desorption/ionization mass spectrometry (Matrix: alpha cyano-4-hydroxycinnaminic acid, mono-isotopic): DECou-GRK (cAB40 
Photolysis Protocol
The photolabile peptide 11 (1 μM) was incubated in 1 mM dithiothreitol and 25 mM Tris pH 7.4 buffer. An aliquot was removed to collect a base line fluorescence measurement using a Photon Technology QM-4 spectrofluorimeter (Birmingham, NJ). The aliquot was returned to stock solution and mixed thoroughly. The sample was then photolyzed using 290 nm to 390 nm (365 nm maximum light intensity) light by an Oriel Hg arc lamp (power supply model 69907 with a 200 Watt Hg lamp, NewPort, North Billerica, MA) using a UG.1 UV bandpass filter (Newport, North Billerica, MA) at various time points at room temperature. After the photolysis period, an aliquot was removed and the fluorescence of the photolyzed material determined. This cycle was repeated until three consecutive fluorescence measurements remained constant to establish a maximum fluorescence enhancement.
Trypsinolysis Protocol
Peptides 5 -10 (1 μM) were incubated in 25 mM Tris pH 7.4 buffer containing 1 mM dithiothreitol in a 200 μL quartz cuvette at 30˚C. After 5 min, a fluorescent baseline was collected using a Photon Technology QM-4 spectrofluorimeter (Birmingham, NJ). Once a stable baseline had been established, 2 µL of trypsin (5 µM; final concentration 50 nM) was added and the fluorescence enhancement was monitored. Experiments were performed in triplicate. Initial rates (<10% of substrate converted to product) were calculated by converting change in fluorescence units/sec to µM product formed/sec.
Absorbance Spectra
Peptides 5, 6, and 8 (15 μM) were incubated in 25 mM Tris pH 7.4 buffer containing 1 mM dithiothreitol in a 200 μL quartz cuvette. After 5 min, the absorbance was collected.
Viscosity and Hydroxypropyl-ß-cyclodextrin Experiments
Peptides 5, 6, and 8 (1 μM) were incubated in 25 mM Tris pH 7.4 buffer containing 1 mM dithiothreitol, 0, 10, 20, 30, 40, or 50 (w/w) PEG400 or 0, 5, 10, 15, 20, 25, or 30 mM hydroxypropyl-ß-cyclodextrin in a 200 μL quartz cuvette at 30 ˚C. After 20 min, fluorescence was collected for each well using a Molecular Devices SpectraMAX Gemini EM fluorescent plate reader (Sunnyvale, CA). Figure S1 . Synthesis of trypsin substrates 5 -10 and the photolabile cassette 1. FmocLys(Mtt)-OH was coupled to the Novasyn TGR-resin to afford S1. The 4-methyltrityl (Mtt) protected amine was subsequently deprotected and acylated with HCTU [1H-benzotriazolium-1 [bis(di-methylamino)-methylene]-5-chloro-hexafluoro-phosphate (1),3-oxide]-activated cAB40 to furnish S2. Trypsin substrates 5 -10 were then prepared by sequentially coupling Fmoc-Arg-OH and Fmoc-Gly-OH to S2 via solid phase peptide synthesis. The photosensitive reporter 11 was constructed in an analogous fashion by sequentially coupling the Fmoc-photolabile linker S3 and Fmoc-Gly-OH. Finally, in each case the fluorophore was coupled using HCTU in DIPEA/DMF. Figure S22 . Assessment of purity of Cou343-GRK(cAB40)-amide 6. RP-HPLC injection of Cou343-GRK(cAB40)-amide 6 on an Alltech Apollo 250 mm x 4.6 mm, 5 μm C18 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 35 min. Figure S23 . Assessment of purity of Cou343-GRK(cAB40)-amide 6. RP-HPLC injection of Cou343-GRK(cAB40)-amide 6 on a Restek Viva 50mm x 2.1 mm, 5 μm C4 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 20 min. Figure S24 . Assessment of purity of FAM-GRK(cAB40)-amide 7. RP-HPLC injection of FAM-GRK(cAB40)-amide 7 on an Alltech Apollo 250 mm x 4.6 mm, 5 μm C18 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 35 min. DMSO was present in the sample, which eluted at 3 min. Figure S28 . Assessment of purity of atto610-GRK(cAB40)-amide 9. RP-HPLC injection of atto610-GRK(cAB40)-amide 9 on an Alltech Apollo 250 x 4.6 mm, 5 μm C18 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 35 min. Figure S29 . Assessment of purity of atto610-GRK(cAB40)-amide 9. RP-HPLC injection of atto610-GRK(cAB40)-amide 9 on a Restek Viva 50 mm x 2.1 mm, 5 μm C4 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 30 min. Figure S30 . Assessment of purity of atto700-GRK(cAB40)-amide 10. RP-HPLC injection of atto700-GRK(cAB40)-amide 10 on an Alltech Apollo 250 mm x 4.6 mm, 5 μm C18 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 35 min. Figure S31 . Assessment of purity of atto700-GRK(cAB40)-amide 10. RP-HPLC injection of atto700-GRK(cAB40)-amide 10 on a Restek Viva 50 mm x 2.1 mm, 5 μm C4 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 30 min. Figure S32 . Assessment of purity of TAM-G-Ø-K(cAB40)-amide 11. RP-HPLC injection of TAM-G-PL-K(cAB40)-amide 11 on an Alltech Apollo 250 mm x 4.6 mm, 5 μm C18 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 35 min. Figure S33 . Assessments of purity of TAM-G-Ø-K(cAB40)-amide 11. RP-HPLC injection of TAM-G-PL-K(cAB40)-amide 11 on a Restek Viva 50 mm x 2.1 mm, 5 μm C4 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 20 min. Figure S34 . Assessment of purity of DEAC-GRK(NH2)-amide 13. RP-HPLC injection of DEAC-GRK(NH2)-amide 13 on an Alltech Apollo 50 mm x 2.1 mm, 5 μm C18 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 12 min. Figure S35 . Assessment of purity of DEAC-GRK(NH2)-amide 13. RP-HPLC injection of DEAC-GRK(NH2)-amide 13 on a Restek Viva 50 mm x 2.1 mm, 5 μm C4 column. The injection was monitored at 220 nm using a 0 -97% linear acetonitrile to water gradient over 12 min. 
